Cited by 52Nicotinic Acetylcholine Receptors StudyPain Mechanisms and TreatmentsPain Management and Opioid Use

Analgesic effects of sazetidine-A, a new nicotinic cholinergic drug

Open access
Cucchiaro, Giovanni, Xiao, Yingxian, Gonzalez-Sulser, Alfredo, Kellar, Kenneth J.·2008·Anesthesiology

Abstract

BACKGROUND: The use of nicotinic agonists for analgesia is limited by their unacceptable side effects. Sazetidine-A is a new partial agonist nicotinic ligand that has very high selectivity for beta2-containing nicotinic acetylcholine receptors. It potently and selectively desensitizes alpha4beta2 nicotinic acetylcholine receptors without measurable effects on alpha3beta4 receptors. The authors investigated the analgesic effects of Sazetidine-A using the formalin model of chronic inflammatory pain. METHODS: The formalin test was conducted after rats received intraperitoneal saline, Sazetidine-A (0.125, 0.25, 0.5, 1, 2 mg/kg), or subcutaneous epibatidine (2.5-5-10 mug/kg). In other experiments, Sazetidine-A was preceded by naloxone (0.5 mg/kg) or mecamylamine (10 mg). Effects of Sazetidine-A and epibatidine on locomotor were tested in an open field, and seizure activity was measured using the Racine scale. Locus coeruleus neuron extracellular single-unit spontaneous discharge was recorded in anesthetized animals after Sazetidine-A and epibatidine. RESULTS: Higher doses of Sazetidine-A (0.5, 1, or 2 mg/kg) induced analgesia, with pain scores significantly lower than those seen after saline, lower doses of Sazetidine-A, and epibatidine (P < 0.001). Naloxone did not antagonize the effects of Sazetidine-A, and mecamylamine had partial, dose-dependent antagonistic effects. Epibatidine excited locus coeruleus neurons, whereas Sazetidine-A had no effect on these neurons. Epibatidine and Sazetidine-A affected animals' locomotor activity for the initial 20 min. While analgesic doses of epibatidine caused seizures, no seizure activity or other neurologic complications were seen in animals that received as much as four times the minimum analgesic dose of Sazetidine-A. CONCLUSIONS: Sazetidine-A seems to be a potent analgesic without causing neurologic side effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/aln.0b013e3181834490

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Perry D, Xiao Y, Nguyen H, Musachio J, Davila-Garcia M, Kellar K: Mea- suring nicotinic receptors with the characteristics of ␣4␤2, ␣3␤2 and ␣3␤4 subtypes in rat tissues by autoradiography. J Neurochem 2002; 82:468-81

Cited by

Sorted by citations

Authors
Cucchiaro, G., Xiao, Y., Gonzalez-Sulser, A., & Kellar, K. J.
Affiliations
  • Assistant Professor.
  • Associate Professor.
  • Research Assistant, Department of Anesthesiology and Critical Care Medicine, University of Pennsylvania School of Medicine.
  • Georgetown University (US)
Venue
Anesthesiology
Published
2008-09-01
Volume
109
Issue
3
Pages
512-519
ISSN
0003-3022 (ISSN-L)
OpenAlex
W2082362344
Cited by
47
References
33
Citations by year
2026: 1 · 2023: 3 · 2021: 5 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 6 · 2013: 4 · 2012: 3
FWCI
2.20
Type
journal article
Language
en
Open access
Locations
  • Anesthesiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Illinois at Urbana-Champaign
  • National Institute on Drug Abuse (DA012976, DA017980, R01DA017980)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
nicotinic agonists, analgesia, formalin test, chronic inflammatory pain, epibatidine, mecamylamine, naloxone, locus coeruleus neurons, locomotor activity, seizures, nicotinic receptor desensitization
MeSH terms
Analgesics, Animals, Azetidines, Disease Models, Animal, Dose-Response Relationship, Drug, Male, Mecamylamine, Motor Activity, Naloxone, Narcotic Antagonists, Pain, Pain Measurement, Pyridines, Receptors, Nicotinic, Sodium Chloride, Rats, Sprague-Dawley, Cholinergic Agents, Nicotinic Agonists, Nicotinic Antagonists, Bridged Bicyclo Compounds, Heterocyclic, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review